Back to results
US 12,180,520 B2Granted
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Benjamin Kleinstiver
Life of this patent
Estimating the term…
Abstract
Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
Claims20
A complex comprising:
- a catalytically inactive Staphylococcus aureus Cas9 (SaCas9) protein comprising an amino acid sequence that has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 2, wherein the amino acid corresponding to E782 of SEQ ID NO:
- 2, the amino acid corresponding to N968 of SEQ ID NO:
- 2, and/or the amino acid corresponding to R1015 of SEQ ID NO:
- 2 is mutated in the SaCas9 protein, and
- a guide RNA having a region complementary to a selected portion of a genome of the cell, wherein the SaCas9 protein is capable of binding to the guide RNA.
3 more elements
Dependencies are inferred from the claim text.